Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026 at 09:58 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

2149611199 1 1 Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

The Company’s Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia–(April 20, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug … Continue reading

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	259.53	-2.90 (-1.11%)
AAPL	340.97	+4.33 (1.29%)
AMD	594.24	-13.86 (-2.28%)
BAC	54.58	+0.26 (0.48%)
GOOG	348.97	+1.11 (0.32%)
META	742.96	+24.29 (3.38%)
MSFT	541.15	+6.08 (1.14%)
NVDA	226.32	-2.96 (-1.29%)
ORCL	137.39	-4.01 (-2.84%)
TSLA	378.03	-4.67 (-1.22%)

Symbol

Price

Change (%)

AMZN

259.53

-2.90 (-1.11%)

AAPL

340.97

+4.33 (1.29%)

AMD

594.24

-13.86 (-2.28%)

BAC

54.58

+0.26 (0.48%)

GOOG

348.97

+1.11 (0.32%)

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

More News

Recent Quotes